Literature DB >> 19969128

Impact of initial surgical margins and residual cancer upon re-excision on outcome of patients with localized breast cancer.

Natalia B Kouzminova1, Sangeeta Aggarwal, Adeeti Aggarwal, Maria D Allo, Albert Y Lin.   

Abstract

BACKGROUND: A significant proportion of patients undergoing breast conservation therapy require additional operations to obtain clear margins. The aim of this study was to assess the impact of initial margins and residual carcinoma found on second surgery on the outcomes of breast cancer patients.
METHODS: In this retrospective study, Cox proportional-hazard regression analysis was performed to evaluate data from 437 patients with stage I to IIIA breast cancer who underwent initial breast-conserving surgery between 1994 and 2004.
RESULTS: The distant recurrence rate was higher among patients with initial positive margins than among those with initial negative margins (15.5% vs 4.9%; hazard ratio, 3.6; 95% confidence interval 1.5-8.7; P = .003). For patients who had underwent second surgery, the finding of a residual invasive carcinoma was associated with increased risk for distant recurrence (22.8% vs 6.6%; hazard ratio, 3.5; 95% confidence interval, 1.8-7.4; P = .0001).
CONCLUSION: Invasive residual carcinoma found during subsequent surgery after initial compromised margins is an important prognostic marker for distant recurrence.

Entities:  

Mesh:

Year:  2009        PMID: 19969128     DOI: 10.1016/j.amjsurg.2009.05.027

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  7 in total

1.  Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging Agent.

Authors:  Julia Parrish-Novak; Kelly Byrnes-Blake; Narine Lalayeva; Stefanie Burleson; Janean Fidel; Rhonda Gilmore; Pamela Gayheart-Walsten; Gregory A Bricker; William J Crumb; K S Tarlo; Stacey Hansen; Valorie Wiss; Errol Malta; William S Dernell; James M Olson; Dennis M Miller
Journal:  Int J Toxicol       Date:  2017-03-17       Impact factor: 2.032

2.  Intraoperative Pathologic Margin Analysis and Re-Excision to Minimize Reoperation for Patients Undergoing Breast-Conserving Surgery.

Authors:  Jennifer M Racz; Amy E Glasgow; Gary L Keeney; Amy C Degnim; Tina J Hieken; James W Jakub; John C Cheville; Elizabeth B Habermann; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2020-07-04       Impact factor: 5.344

3.  Multi-class classification of breast tissue using optical coherence tomography and attenuation imaging combined via deep learning.

Authors:  Ken Y Foo; Kyle Newman; Qi Fang; Peijun Gong; Hina M Ismail; Devina D Lakhiani; Renate Zilkens; Benjamin F Dessauvagie; Bruce Latham; Christobel M Saunders; Lixin Chin; Brendan F Kennedy
Journal:  Biomed Opt Express       Date:  2022-05-12       Impact factor: 3.562

4.  The ongoing revolution in breast imaging calls for a similar revolution in breast pathology.

Authors:  L Tabár; P B Dean; N Lindhe; M Ingvarsson
Journal:  Int J Breast Cancer       Date:  2012-09-30

5.  Rapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgery.

Authors:  Edward R St John; Julia Balog; James S McKenzie; Merja Rossi; April Covington; Laura Muirhead; Zsolt Bodai; Francesca Rosini; Abigail V M Speller; Sami Shousha; Rathi Ramakrishnan; Ara Darzi; Zoltan Takats; Daniel R Leff
Journal:  Breast Cancer Res       Date:  2017-05-23       Impact factor: 6.466

6.  Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics.

Authors:  R Jeevan; D A Cromwell; M Trivella; G Lawrence; O Kearins; J Pereira; C Sheppard; C M Caddy; J H P van der Meulen
Journal:  BMJ       Date:  2012-07-12

7.  Multiplexed Molecular Imaging of Biomarker-Targeted SERS Nanoparticles on Fresh Tissue Specimens with Channel-Compressed Spectrometry.

Authors:  Soyoung Kang; Yu Wang; Nicholas P Reder; Jonathan T C Liu
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.